Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AbbVie (NY:ABBV)

184.02 +2.34 (+1.29%)
Official Closing Price Updated: 7:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
3 Biopharmaceutical Stocks Bucking the Sell-Off
Three biopharma companies may appeal to investors looking for firms that have not been rocked by tariff-inspired turbulence. 
Via MarketBeat
Topics World Trade
Exposures Product Safety Tariff
The Last Time the Stock Market Started a Year This Badly Was 2022. Is Another Crash Coming?
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
What's going on in today's session: S&P500 movers
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday. 
Via Chartmill
These S&P500 stocks are gapping in today's session
Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session. 
Via Chartmill
Tech Stocks Rebound As US Treasuries Tumble: What's Driving Markets Wednesday?
Wall Street saw a tentative tech rebound early Wednesday, as investors begin to shrug off escalating U.S.-China trade tensions following a steep market selloff. 
Via Benzinga
Topics World Trade
Exposures Tariff
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Exposures Political Tariff US Equities
Elliott Wave Technical Analysis: AbbVie Inc. - Wednesday, April 9
ABBV is currently showing a pronounced move down in both daily and 1-hour charts, suggesting a deeper ZigZag correction in play. 
Via Talk Markets
Topics Stocks / Equities
2 Top Dividend Stocks That Could Set You Up for Life
Via The Motley Fool
Topics Government Initial Public Offering Intellectual Property
Exposures Intellectual Property Political Securities Market
Dr. Oz Officially Confirmed as Head of the Centers for Medicare and Medicaid Services. Here's What Retirees Need to Know So Far.
Via The Motley Fool
Topics Government
Exposures Political
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Topics Economy Intellectual Property
Exposures Economy Intellectual Property
2 Dividend Stocks to Buy Hand Over Fist in April
Via The Motley Fool
Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More
President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here's a look at which products and sectors are... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
3 High-Yielding Dividend Stocks That Retirees Can Buy and Forget About
Via The Motley Fool
Biotech Stocks Dive After Trump Tacks On 20% European Tariff. Why AbbVie, Merck Could Be Exposed.
It's unclear whether pharmaceutical goods could be exempt from tariffs. A number of drugmakers manufacture ingredients abroad. 
Via Investor's Business Daily
Topics Economy Government World Trade
Exposures Political Supply Chain Tariff
Looking At AbbVie's Recent Unusual Options Activity
Via Benzinga
Decoding AbbVie's Options Activity: What's the Big Picture?
Via Benzinga
Meta, Snowflake, PayPal And Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Via The Motley Fool
Topics Intellectual Property Retirement
Exposures Intellectual Property Pension
MarketBeat Week in Review – 03/24 - 03/28
Markets got a double dose of bad news about inflation and consumer confidence; next week, the Trump tariffs and Jobs report are likely to keep volatility high 
Via MarketBeat
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
3 Relatively Safe Stocks to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Exposures Economy Political Tariff
Retired At 58, He 'Spent Between $1M-$2M On Stocks' – Investor Who Built An 8% Yield Portfolio And Lives Off Dividends Shares Top Holdings
Via Benzinga
From Rookie Mistakes To $10K/Year In Dividends – Military Veteran Who 'Made A Few Great Plays' Shares His 10 Biggest Bets
Via Benzinga
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Via The Motley Fool
Stocks Going Ex Dividend In April 2025
The following is a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
Topics Stocks / Equities
What's going on in today's session: S&P500 movers
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside
Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates coverage with a $36 price target. 
Via Benzinga
Tuesday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.